#LEQEMBI News
Eisai to offer Alzheimer's drug in China from July
asia.nikkei.com TOKYO-- Eisai will launch its treatment for Alzheimer's disease in China this July with a major health care provider there under plans announced Wednesday, entering the…
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early…
benzinga.com TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. BIIB Corporate headquarters:…